Table 3.

Kinase inhibitors and concentrations used in the study

Inhibitors	IC50	Concentration used (µM)	Kinases inhibited
RO-318220	PKC-α, -β, -γ (5–27 nM)	0.5–2	PKC-α, -β, -γ
	PKC-ξ (100 nM)		PKC-ξ
	PKA (900 nM)		PKA
	GSK3 (38 nM)		GSK3
	MSK1 (8 nM)		MSK1
	P70 S6K (15 nM)		P70 S6K
	RSK2 (3 nM)		RSK2
	PKC (8–39 nM)		PKA-α, -β1, -β2, -γ, -ε
	PKA (2–8 µM)
RO-318425	Phosphorylase kinase (1.3 µM)	2	Phosphorylase kinase
	MLCK (2.7 µM)
RO-320432	PKCs (1–10 µM)	2	PKC-α, -β1, -β2, -γ, -ε
LY294002	PI3K (10 µM)	50	PI3K
Wortmannin	PI3K (50–450 nM)	0.5–5	PI3K

PKC, protein kinase C; PKA, protein kinase A; GSK3, glycogen synthase kinase 3; MSK1, mitogen- and stress-activated kinase 1; P70 S6K, p70 ribosomal S6 kinase; RSK2, ribosomal S6 kinase 2; MLCK, myosin light chain kinase; PI3K, phosphatidylinositol 3-kinase.